AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 292: H1619-H1629, 2007. First published October 20, 2006; doi:10.1152/ajpheart.00140.2006
0363-6135/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/3/H1619    most recent
00140.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, S.
Right arrow Articles by Rozanski, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, S.
Right arrow Articles by Rozanski, G. J.

Insulin regulation of glutathione and contractile phenotype in diabetic rat ventricular myocytes

Shumin Li,1 Xun Li,1,4 Yu-Long Li,1 Chun-Hong Shao,3 Keshore R. Bidasee,3 and George J. Rozanski1,2

1Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska; 2Center for Redox Biology, University of Nebraska-Lincoln, Lincoln, Nebraska; 3Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska; and 4Department of Cardiology, The First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China

Submitted 7 February 2006 ; accepted in final form 17 October 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cardiovascular complications of diabetes mellitus involve oxidative stress and profound changes in reduced glutathione (GSH), an essential tripeptide that controls many redox-sensitive cell functions. This study examined regulation of GSH by insulin to identify mechanisms controlling cardiac redox state and to define the functional impact of GSH depletion. GSH was measured by fluorescence microscopy in ventricular myocytes isolated from Sprague-Dawley rats made diabetic by streptozotocin, and video and confocal microscopy were used to measure mechanical properties and Ca2+ transients, respectively. Spectrophotometric assays of tissue extracts were also done to measure the activities of enzymes that control GSH levels. Four weeks after injection of streptozotocin, mean GSH concentration ([GSH]) in isolated diabetic rat myocytes was ~36% less than in control, correlating with decreased activities of two major enzymes regulating GSH levels: glutathione reductase and {gamma}-glutamylcysteine synthetase. Treatment of diabetic rat myocytes with insulin normalized [GSH] after a delay of 3–4 h. A more rapid but transient upregulation of [GSH] occurred in myocytes treated with dichloroacetate, an activator of pyruvate dehydrogenase. Inhibitor experiments indicated that insulin normalized [GSH] via the pentose pathway and {gamma}-glutamylcysteine synthetase, although the basal activity of glucose-6-phosphate dehydrogenase was not different between diabetic and control hearts. Diabetic rat myocytes were characterized by significant mechanical dysfunction that correlated with diminished and prolonged Ca2+ transients. This phenotype was reversed by in vitro treatment with insulin and also by exogenous GSH or N-acetylcysteine, a precursor of GSH. Our data suggest that insulin regulates GSH through pathways involving de novo GSH synthesis and reduction of its oxidized form. It is proposed that a key function of glucose metabolism in heart is to supply reducing equivalents required to maintain adequate GSH levels for the redox control of Ca2+ handling proteins and contraction.

redox; cardiomyopathy; pentose pathway

DIABETES IS ASSOCIATED WITH a unique cardiomyopathy that is independent of vascular disease and that contributes to a greater propensity for heart failure and arrhythmias in diabetic individuals than the general population (32, 40). The onset of clinical diabetic cardiomyopathy is marked by a slowing in relaxation kinetics and diastolic dysfunction; however, as the syndrome progresses, systolic dysfunction emerges, exacerbating the overall decline in ventricular performance (14). The depressed contractile features of the diabetic heart are proposed to be due to perturbations in Ca2+ handling, actin-myosin interactions, or a combination of both (32, 40). Although changes in expression of Ca2+ handling and myofilament proteins have been shown in experimental models of diabetic cardiomyopathy, it is also well recognized that posttranslational modification of these proteins can significantly affect contractile performance in the absence of or in addition to changes in expression. One type of protein modification that may play a central role is the reversible oxidation of amino acid side chains, particularly those of cysteine and methionine residues (9, 10, 36, 38). These residues are susceptible to modification by a variety of reactive oxygen species and their by-products.

Clinical and experimental studies suggest that ventricular dysfunction associated with diabetes mellitus is linked to a multitude of metabolic disturbances that result in increased production of reactive oxygen species and pathophysiological changes in myocyte function (8, 12). In mammalian cells, the reduced form of the tripeptide glutathione (GSH) is an important buffer against reactive oxygen species and hydroperoxides. For example, GSH is a radical scavenger that directly neutralizes carbon-centered radicals, superoxide anion, and hydroxyl radicals (10, 48). GSH is also an essential cofactor for inactivation of hydroperoxides by glutathione peroxidase and for the conjugation of cytotoxic by-products of lipid peroxidation by glutathione-S-transferase (10). Recent studies have shown that disease states for which oxidative stress is a contributing factor, such as diabetes, elicit dynamic and profound alterations in cardiac GSH, which concurrently impact cell redox state (11, 46, 50, 51). Most notably, GSH depletion and increased content of oxidized cellular proteins have been shown to play important roles in the pathogenesis of chronic diabetes (8, 11, 50). Many of the pathogenic changes elicited in early stages of diabetes can be reversed or prevented by manipulating endogenous pathways affecting intracellular GSH concentration ([GSH]), indicating that GSH is essential to cell viability and normal cell function (50).

It has recently been proposed that pathways of glucose metabolism are involved in the control of myocardial GSH (1, 31, 35, 42, 50). In the case of diabetes, the well-documented decrease in myocardial insulin signaling and glucose utilization (19, 34) are likely factors contributing to alterations in GSH status. Accordingly, insulin replacement therapy in Type 1 diabetic models maintains normal cardiac GSH levels (31, 43, 51). Recent data from our laboratory also provide functional evidence for a link between glucose metabolism and cell GSH. For example, upregulation of voltage-gated K+ channels in diabetic rat ventricular myocytes by insulin is blocked by inhibitors of GSH metabolism and is mimicked by exogenous GSH (50). These and related studies (35) support the notion that an important effect of insulin signaling pathways on cardiac function is the regulation of [GSH] and the control of cell redox state.

The present study examined mechanisms of GSH regulation in the setting of diabetic cardiomyopathy. Our data suggest that GSH depletion in the diabetic heart involves loss of function of major GSH enzymes and decreased substrate availability for glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting step of the pentose pathway. This shift in GSH status is associated with depressed myocyte mechanical function and Ca2+ transients. Furthermore, in vitro insulin treatment of diabetic rat myocytes normalizes [GSH], mechanical properties, and Ca2+ transients via pathways involving G6PD and GSH synthesis. Contraction and Ca2+ handling are also normalized by exogenous GSH or N-acetylcysteine (NAC). These results support the hypothesis that an essential function of glucose metabolism in the heart is the supply of NADPH via the pentose pathway to maintain adequate GSH levels for the redox control of intracellular Ca2+ handling and contraction.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Induction of diabetes and isolation of myocytes. Animal experimentation was approved by the Animal Care and Use Committee of the University of Nebraska Medical Center, and this investigation conformed with the Guide for the Care and Use of Laboratory Animals (NIH Publication 85-23, revised 1996). Male Sprague-Dawley rats weighing 220–225 g were made diabetic by a single intraperitoneal injection of streptozotocin (STZ) at a dose of 65 mg/kg. Blood glucose levels were measured 3 days after STZ injection to confirm hyperglycemia. Normal rats of similar age and weight injected with vehicle only (1 mmol/l citrate buffer, pH 4.5) were used as controls. Diabetic rats at the end of our study period exhibited a nearly fourfold increase in blood glucose concentration compared with control rats (diabetic: 21.9 ± 0.7 mmol/l, n = 30; control: 5.5 ± 0.3 mmol/l, n = 26; P < 0.05), which was correlated with a significant decrease in immunoreactive serum insulin levels (diabetic: 0.3 ± 0.01 ng/ml; control: 2.0 ± 0.02 ng/ml; P < 0.05) as measured by a commercial kit (Alpo Diagnostics, Uppsala, Sweden). As in our previous study (49), body weight for the diabetic group (269.9 ± 3.0 g) was significantly less than for control animals (293.4 ± 2.9 g; P < 0.05). With this duration of diabetic conditions, heart weight-to-body weight ratio remains essentially unchanged from control (49).

Four to five weeks after STZ or vehicle injection, rats were given an overdose of pentobarbital sodium (150 mg/kg ip), and single ventricular myocytes were dissociated from excised, perfused hearts by a collagenase digestion protocol described previously (27, 35, 49, 50). The atria were discarded after the digestion procedure, and the dissociated myocytes from all ventricular regions were suspended in DMEM and incubated at 37°C until used, usually within 6 h of isolation. In some experiments, myocytes were maintained in culture for up to 24 h. For studies of intracellular GSH and Ca2+ transients, isolated myocytes were first seeded on laminin-coated glass coverslips.

Measurement of intracellular GSH. Intracellular [GSH] was measured by fluorescence microscopy using the probe monochlorobimane (mBCl; Molecular Probes, Eugene, OR) as described previously (27). Briefly, glass coverslips with attached myocytes were transferred to a culture dish filled with a loading solution containing (in mmol/l) 138 NaCl, 4.0 KCl, 1.2 MgCl2, 1.8 CaCl2, 18 glucose, 5 HEPES, and 0.4 mBCl. This solution also contained 2 mmol/l probenecid to inhibit transporter-mediated export of the GSH-bimane adduct. Cells were loaded with mBCl for 50–60 min at room temperature and then transferred to a recording chamber mounted on the stage of an inverted microscope (Nikon Diaphot, Melville, NY). After washout of extracellular probe, myocytes were illuminated with light at 360 nm by means of a Deltascan monochromator system (Photon Technology International, Lawrenceville, NJ). A 15 x 15-µm optical sampling window was positioned over the center of each myocyte, and emission fluorescence (460 nm) was collected with a photometer assembly. For all experiments, only Ca2+-tolerant, rod-shaped myocytes with clear cross striations were chosen for GSH measurement because these empirical criteria are correlated with the functional integrity of isolated myocytes (35, 49, 50). [GSH] was calculated from calibration curves generated with graded concentrations of GSH (7.8–1,000 µmol/l) plus rat liver glutathione-S-transferase (0.2 U/ml) to generate the fluorescent GSH-bimane adduct (27). Fluorescence data were collected from each myocyte for 30–60 s to verify steady-state conditions. If fluorescence varied by more than 5% during this recording period, data from that myocyte were excluded from analysis. Measured fluorescence was converted to [GSH] (in amol/µm3) using the calibration curve, the known dimensions of the sampling window, and an estimate of cell thickness derived from a previous study (27).

GSH was also measured in myocyte lysates using a commercial kit (Oxis Research, Portland, OR), which is based on an enzymatic recycling assay described by Tietze (45) and used in our previous studies (50). Briefly, suspensions of isolated myocytes were sonicated in 5% metaphosphoric acid to precipitate proteins, centrifuged at 4°C for 20 min (3000 g), and the supernatant was collected for assay. Total glutathione [GSH + oxidized glutathione (GSSG)] was measured in 100-µl samples of supernatant by recording the formation of 2-nitro-5-thiobenzoic acid at 412 nm (25°C) in the presence of 5,5'-dithio-bis-(2-nitrobenzoic acid), NADPH, glutathione reductase, and EDTA. GSSG was determined by derivatizing 150-µl samples of supernatant with 1-methyl-2-vinylpyridium trifluoromethane sulfonate and assaying 100-µl aliquots of the derivatized sample as above for total GSH. Standard curves for GSH and GSSG were constructed, and the [GSH] was calculated by subtracting the GSSG concentration from total glutathione (GSH+GSSG). Measured concentrations of GSH and GSSG were expressed in micromoles per liter per milligram protein and as a ratio (GSH/GSSG).

Mechanical properties and intracellular Ca2+ transients. Mechanical properties of isolated ventricular myocytes were assessed with a video-based edge-detection system (IonOptix, Milton, MA). Briefly, cells were placed in a perfusion chamber mounted on the stage of an inverted microscope (X-40; Zeiss, Thornwood, NJ) and superfused with room temperature (25°C) standard external solution containing (in mmol/l) 138 NaCl, 4.0 KCl, 1.2 MgCl2, 1.8 CaCl2, 18 glucose, and 5 HEPES, pH 7.4. Cells were field stimulated (10 V, 10 ms) at 0.5 Hz through a pair of platinum wires placed on opposite sides of the chamber. The extent of myocyte shortening and rates of shortening and relengthening were measured by IonWizard software (version 5.0; IonOptix).

To measure Ca2+ transients, myocytes attached to laminin-coated glass coverslips were loaded with Fluo 3 (5 µmol/l) for 30 min at 37°C using the same external solution as for contraction studies. At the end of the incubation period, cells were washed with external solution to remove extracellular Fluo 3 and placed in a chamber on the stage of a laser confocal microscope (confocal LSM 410; Zeiss) equipped with an argon-krypton laser (25-mW argon laser, 0.5% intensity, x100 lens). Cells superfused with room temperature external solution were then field stimulated at 0.5 Hz (10 V, 10 ms), and changes in fluorescence intensities were determined. Fluo 3 was excited by light at 488 nm, and fluorescence was measured at wavelengths of >515 nm. The rate of increase of fluorescence was determined with linear regression analysis, and fluorescence decay was measured as the time to 50% decrease from the peak value.

Enzymes regulating GSH. In a separate group of rats, the activities of glutathione reductase, {gamma}-glutamylcysteine synthetase, and G6PD were measured in ventricular tissue samples by spectrophotometric methods. Glutathione reductase activity was measured by the technique of Carlberg and Mannervik (4). Briefly, 50- to 100-mg tissue samples were homogenized in ice-cold Tris buffer (0.1 mol/l, pH 8.0, with 2 mmol/l EDTA) and centrifuged at 4°C (6,000 g) for 30 min. A 200-µl aliquot of the supernatant was added to a cuvette containing KH2PO4 buffer (0.2 mol/l, pH 7.0) plus 2 mmol/l EDTA, 20 mmol/l GSSG, and 2 mmol/l NADPH. The change in absorbance at 340 nm was monitored for 5 min at 30°C by a spectrophotometer (ThermoSpectronic, Waltham, MA). A milliunit (mU) of glutathione reductase activity was defined as the amount of enzyme catalyzing the reduction of 1 nmol NADPH per minute.

{gamma}-Glutamylcysteine synthetase activity was determined by the method of Seelig and Meister (37). Ventricular tissue samples were prepared as above, and a 50-µl aliquot of supernatant was added to a reaction mixture containing 0.1 mol/l Tris buffer and (in mmol/l) 150 KCl, 5 Na2ATP, 2 phosphoenolpyruvate, 10 L-glutamate, 10 L-{alpha}-aminobutyrate, 20 MgCl2, 2 Na2-EDTA, 0.2 NADH, 17 µg pyruvate kinase and 17 µg lactate dehydrogenase. The change in absorbance at 340 nm was monitored for 5 min at 37°C, and {gamma}-glutamylcysteine synthetase activity was expressed in milliunits, defined as the activity converting 1 nmol of NADH to NAD per minute.

G6PD activity was measured with a commercial kit (OxisResearch, Foster City, CA). Briefly, ventricular tissue samples were homogenized in supplied diluent and centrifuged at 4°C (6,000 g) for 30 min. A 50-µl aliquot of supernatant was added to a reaction mixture containing NADP, glucose-6-phosphate, and 6-phosphogluconic acid. The change in absorbance at 340 nm in the presence of both substrates was measured at 37°C for 5 min. A second aliquot of supernatant was added to a reaction mixture containing NADP plus 6-phosphogluconic acid alone, and absorbance was again measured at 340 nm. G6PD activity was calculated by subtracting the rate of change in absorbance with 6-phosphogluconic acid alone from that measured with the combined substrates to eliminate the contribution of 6-phosphogluconate dehydrogenase to total NADPH production, thus yielding a more accurate estimation of rate-limiting G6PD activity. The net change in absorbance was expressed in milliunits, defined as the enzyme activity producing 1 nmol of NADPH per minute. Activities for {gamma}-glutamylcysteine synthetase, glutathione reductase, and G6PD were normalized per milligram protein, measured by a commercial kit (Pierce Biotechnology, Rockford, IL).

Before intracellular GSH, Ca2+ transients, or mechanical properties were measured, isolated myocytes were maintained in culture medium at 37°C in the absence or presence of one of two activators of glucose utilization: insulin (100 nmol/l) or dichloroacetate (DCA; 1.5 mmol/l). To examine regulatory pathways, myocytes were pretreated with different inhibitors of GSH metabolism before addition of insulin. Specifically, G6PD was inhibited by pretreating myocytes for 30 min with dehydroepiandrosterone (DHEA; 30 µmol/l) or 6-aminonicotinamide (6-AN, 1 mmol/l) before cells were stimulated with insulin for 3–4 h. Inhibition of GSH synthesis by {gamma}-glutamylcysteine synthetase was achieved by preincubating myocytes for 24 h with buthionine sulfoximine (50 µmol/l) before addition of insulin. Previous studies have shown that prolonged exposure to this specific blocker is required to effectively inhibit {gamma}-glutamylcysteine synthetase (26). The respective working concentrations of blockers used in our studies were chosen to elicit ~50% inhibition of the target enzyme as based on previous studies (24, 26, 53). Unless stated otherwise, all reagents used in our experiments were purchased from Sigma-Aldrich (St. Louis, MO).

Statistical analysis. All results are expressed as means ± SE. Comparisons of two groups were made with Student's t-test, whereas more than two groups were compared by ANOVA. When a significant difference among groups was indicated by the initial analysis, individual paired comparisons were made by Dunnett's t-test. Differences were considered significant at P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Upregulation of GSH by insulin and DCA. Figure 1A compares mean data from fluorescence microscopy measurements of [GSH] in ventricular myocytes from control and diabetic rats. In general, mean [GSH] in diabetic rat myocytes was 30–40% less than in controls (P < 0.05) and was unchanged for up to 6 h of culture after cell isolation without any further experimental treatment. Moreover, diabetes-induced GSH depletion was similar throughout the 4- to 5-wk period of diabetic conditions examined in this study: mean [GSH] in myocytes from diabetic rats studied at 4 and 5 wk was 2.4 ± 0.1 amol/µm3 (n = 108 myocytes from 9 rats) and 2.3 ± 0.1 amol/µm3 (n = 122 myocytes from 8 rats), respectively. We also compared the change in [GSH] observed with our fluorescence microscopy technique with measurements of GSH/GSSG in suspensions of isolated myocytes using a standard spectrophotometric assay (45, 50). These latter analyses showed that GSH/GSSG was significantly decreased in the diabetic group by 33% (1.6 ± 0.08, n = 5 hearts) compared with control (2.4 ± 0.1, n = 6 hearts; P < 0.05), verifying conditions of oxidative stress.


Figure 1
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 1. Reduced glutathione concentration ([GSH]) in isolated ventricular myocytes. A: mean data from control and diabetic rat myocytes studied after 1–2, 3–4, and 5–6 h of incubation. Numbers in parentheses represent number of myocytes studied per group. Data were collected from 5 control and 11 diabetic rats. *P < 0.05 compared with control. B and C: tissue samples from left ventricle (LV), septum (SE), and right ventricle (RV) were assayed for {gamma}-glutamylcysteine synthetase ({gamma}-GCS; B) or glutathione reductase (GR; C) activity. Number of hearts assayed in each group is shown in parentheses. *P < 0.05 compared with control.

 
Because cellular GSH content is determined by the balance of GSH utilization and production, we measured the activities of two major enzymes involved in controlling GSH levels. In Fig. 1, B and C, basal activities of {gamma}-glutamylcysteine synthetase and glutathione reductase in ventricular tissue samples from control and diabetic rats are compared. As shown, these enzymes were mainly inhibited in the diabetic group compared with control, although the activities were not uniformly decreased throughout the heart. The largest changes were observed in samples from left ventricle, where {gamma}-glutamylcysteine synthetase and glutathione reductase were decreased by 52 and 33%, respectively (P < 0.05). By comparison, tissue samples from the right ventricle showed the least amount of change. Although mean glutathione reductase activity in the right ventricle of diabetic rats was decreased from control by 31%, this change did not reach statistical significance (P = 0.09). Our group (27) previously found no significant regional variations in [GSH] in control or GSH-depleted myocytes. Thus, in the fluorescence microscopy experiments outlined below, we used a mixed population of ventricular myocytes and did not analyze regional differences in the control of [GSH].

As shown above in Fig. 1A, the decreased [GSH] in diabetic rat myocytes compared with control was stable under basal culture conditions for up to 6 h. However, Fig. 2A shows that [GSH] was upregulated by insulin or the pyruvate dehydrogenase activator DCA. Specifically, addition of 100 nmol/l insulin or 1.5 mmol/l DCA to the culture medium significantly increased [GSH] in diabetic rat myocytes but with different time courses. After 1–2 h of incubation with insulin, [GSH] was not different from untreated myocytes from the same group (2.4 ± 0.1 amol/µm3, n = 62), whereas the same duration of DCA treatment significantly increased [GSH] to near control levels (see Fig. 1A). By 3–4 h, both insulin and DCA had significantly increased [GSH] to control levels, whereas at the 5- to 6-h time point [GSH] remained elevated in insulin-treated cells but was decreased in the DCA-treated group (P < 0.05). Figure 2B shows that [GSH] in control myocytes was not significantly affected by insulin treatment up to 5–6 h; however, as in diabetic rat myocytes (Fig. 2A), DCA treatment for 5–6 h decreased [GSH] in control cells. Because of the depletion of GSH elicited by prolonged exposure to DCA, we conducted subsequent experiments using insulin as a metabolic agonist to further define the mechanisms of GSH regulation.


Figure 2
View larger version (22K):
[in this window]
[in a new window]

  		Fig. 2. A: upregulation of [GSH] in diabetic rat myocytes (no. of myocytes shown in parentheses) by 100 nmol/l insulin or by 1.5 mmol/l dichloroacetate (DCA). Data were collected from 8 and 6 diabetic rats for insulin-treated and DCA-treated groups, respectively. *P < 0.05 compared with diabetic + insulin group. B: effect of 100 nmol/l insulin or 1.5 mmol/l DCA on [GSH] in control myocytes (no. of myocytes shown in parentheses). Data for both groups were collected from 3 rats. *P < 0.05 compared with control + insulin group.

 
Pathways regulating GSH. The cellular effectors mediating upregulation of [GSH] by insulin in diabetic rat myocytes were examined in an additional series of experiments with blocking agents that target the GSH system at different sites. We first tested the effects of two structurally distinct inhibitors of G6PD, DHEA (30 µmol/l) and 6-AN (1 mmol/l). G6PD is the rate-limiting enzyme of the pentose pathway that generates NADPH required by glutathione reductase to convert GSSG to GSH (4, 9, 36–38). As shown in Fig. 3A, DHEA and 6-AN each blocked the effect of insulin to normalize [GSH] in the diabetic rat myocytes. Separate experiments done in cell suspensions also showed that DHEA blocked the insulin-mediated increase in GSH/GSSG (untreated: 1.6 ± 0.08, n = 6 hearts; insulin-treated: 2.2 ± 0.2, n = 5 hearts; P < 0.05; DHEA-treated: 1.4 ± 0.1, n = 6 hearts; DHEA plus insulin: 1.6 ± 0.1, n = 6 hearts). However, fluorescence microscopy studies showed that each inhibitor alone significantly decreased [GSH] compared with that shown for untreated diabetic myocytes. This suggested that insulin-sensitive regulation of [GSH] in diabetic rat myocytes involved pathways in addition to G6PD. Thus additional experiments were done in diabetic rat myocytes pretreated with the {gamma}-glutamylcysteine synthetase inhibitor buthionine sulfoximine (50 µmol/l) for 24 h and exposed to insulin in the presence of DHEA or 6-AN. Figure 3B shows that pretreatment with buthionine sulfoximine decreased basal [GSH] by 22% from untreated diabetic rat myocytes (P < 0.05) but that insulin still significantly increased [GSH], a response that was completely blocked by the addition of DHEA or 6-AN. In contrast to their effects on diabetic rat myocytes, neither DHEA nor 6-AN alone for 3–4 h significantly altered [GSH] in control myocytes (DHEA-treated: 3.6 ± 0.2 amol/µm3, n = 24; 6-AN-treated: 3.5 ± 0.2 amol/µm3, n = 21; untreated: 3.9 ± 0.2 amol/µm3, n = 21), whereas buthionine sulfoximine similarly decreased [GSH] by 24% (untreated: 3.8 ± 0.2 amol/µm3, n = 10; buthionine sulfoximine-treated: 2.9 ± 0.1 amol/µm3, n = 10; P < 0.05).


Figure 3
View larger version (26K):
[in this window]
[in a new window]

  		Fig. 3. Effect of glucose-6-phosphate dehydrogenase (G6PD) and {gamma}-GCS inhibitors on GSH response to insulin. A: diabetic rat myocytes (n shown in parentheses) were incubated with 100 nmol/l insulin for 3–4 h with or without G6PD inhibitors dehydroepiandrosterone (DHEA; 30 µmol/l) or 6-aminonicotinamide (6-AN; 1 mmol/l). Data from untreated myocytes are also shown. *P < 0.05 compared with untreated myocytes. B: myocytes from diabetic rat hearts (n shown in parentheses) were preincubated with 50 µmol/l buthionine sulfoximine (BSO) for 24 h before treatment with DHEA or 6-AN. Data in A and B were collected from 2–6 diabetic rats. *P < 0.05 compared with untreated myocytes. C: basal activity of G6PD in tissue samples from the septum. D: activities of {gamma}-GCS and GR in insulin-treated diabetic rat myocytes. Data were normalized to the mean activity of untreated myocytes. *P < 0.05 compared with untreated diabetic group. In C and D, numbers in parentheses (in key) represent number of hearts assayed.

 
Because data from the DHEA and 6-AN experiments in diabetic rat myocytes suggest that G6PD plays a key role in GSH homeostasis, we assayed tissue samples from septum to determine whether this enzyme contributed to GSH depletion under diabetic conditions. However, as shown in Fig. 3C, G6PD activity in our diabetic model was not different from control. Finally, we assessed the effects of insulin on the other major GSH-related enzymes. Figure 3D shows that insulin treatment of diabetic rat myocytes significantly increased {gamma}-glutamylcysteine synthetase activity but had no effect on glutathione reductase. In control myocytes, both enzymes were unaffected by insulin (data not shown) as was [GSH] (Fig. 2B). Likewise, insulin treatment of control cells had no significant effect on GSH/GSSG (insulin treated: 2.4 ± 0.1, n = 5 hearts; untreated: 2.4 ± 0.1, n = 6 hearts).

Insulin regulation of mechanical properties and Ca2+ transients. The functional impact of diabetes-induced GSH dysregulation was analyzed in relation to changes in mechanical properties and Ca2+ transients as measured in field-stimulated myocytes at room temperature. Our model of diabetes, as in other studies (6), was marked by significant decreases in myocyte mechanical activity and prolonged kinetics of Ca2+ transients when compared with controls. Figure 4 A shows superimposed length changes in a control and diabetic rat myocyte paced at 0.5 Hz. In addition to a marked decrease in the extent of shortening, the diabetic rat myocyte was characterized by profound decreases in the rate of shortening and relengthening compared with control. These changes in mechanical properties correlated closely with alterations in evoked Ca2+ transients (Fig. 4B). The line scans (Fig. 4B, top) illustrate that the evoked Ca2+ release from control and diabetic rat myocytes was uniform throughout the length of these cells. However, the traces (Fig. 4B, bottom) show that the rate of Ca2+ rise, the peak Ca2+ release, and the Ca2+ decay kinetics were suppressed in the diabetic rat myocyte compared with the control cell. Mean data from cell length and Ca2+ transient studies are summarized in Table 1, which also shows the effect of insulin treatment. In our contraction studies, insulin treatment of diabetic rat myocytes for 3–4 h normalized the rates of cell shortening (–dL/dt) and relengthening (+dL/dt) and percent shortening, whereas these parameters were unaffected by insulin in control myocytes. Similar to regulation of GSH (Fig. 3B), the effect of insulin on mechanical parameters in diabetic rat myocytes was blocked by pretreating cells with DHEA plus buthionine sulfoximine. Insulin also normalized kinetic parameters and peak Ca2+ release in Ca2+ transient studies.


Figure 4
View larger version (30K):
[in this window]
[in a new window]

  		Fig. 4. Myocyte mechanical properties and Ca2+ transients. Isolated myocytes from control and diabetic rats were field stimulated at 0.5 Hz in room temperature external solution containing 1.8 mmol/l Ca2+. A: superimposed mechanical responses from a control and a diabetic rat myocyte. B, top: representative line scans of Ca2+ transients evoked in a control and diabetic rat myocyte preloaded with fluo 3-AM and field stimulated at 0.5 Hz. B, bottom: Ca2+ signals shown represent changes in fluorescence (F) ratio ([F – F0]/F0) expressed in arbitrary fluorescence units (fau). Color bars (left of line scans) show the strength of the fluorescent signal.

 

View this table:
[in this window]
[in a new window]

  		Table 1. Effect of in vitro insulin treatment on myocyte mechanical properties and Ca2+ transients

 
Because insulin normalized [GSH], Ca2+ transients, and mechanical properties in diabetic rat myocytes, we next tested the functional role of GSH by incubating myocytes for 3–4 h with exogenous GSH or NAC, a GSH precursor. Figure 5A shows concentration-response data for GSH and NAC on mechanical properties (–dL/dt, +dL/dt, %shortening) of diabetic rat myocytes. The changes in mechanical properties elicited by GSH and NAC were similar over the concentration range of 0.1–10 mmol/l, but significance only occurred at 10 mmol/l, which was the test concentration used in all subsequent experiments. Figure 5B shows that, in contrast to diabetic rat myocytes, neither 10 mmol/l GSH nor NAC significantly affected mechanical parameters in control myocytes. Although these exogenous reductants significantly improved mechanical function in diabetic rat myocytes, they did not normalize all measured parameters. Specifically, in diabetic rat myocytes treated with GSH, –dL/dt (139.8 ± 9.4 µm/s) and percent shortening (10.8 ± 0.3%) were significantly less than in comparably treated control myocytes (201.5 ± 27.6 µm/s and 12.3 ± 0.5%, respectively; P < 0.05). +dL/dt in GSH-treated diabetic cells was also less than in controls (143.0 ± 10.2 vs. 169.8 ± 17.3 µm/s), but this difference was not significant (P = 0.16). Similar differences in mechanical properties were also observed in NAC-treated diabetic and control myocytes (data not shown).


Figure 5
View larger version (32K):
[in this window]
[in a new window]

  		Fig. 5. Effect of exogenous GSH and N-acetylcysteine (NAC) on mechanical parameters. A: diabetic rat myocytes were preincubated for 3–4 h with 0, 0.1, 1, or 10 mmol/l GSH or NAC. Maximum rates of myocyte shortening (–dL/dt) and relengthening (+dL/dt) and percent shortening were measured at 0.5 Hz. *P < 0.05 compared with untreated myocytes. B: mechanical properties of control myocytes pretreated with 10 mmol/l GSH or NAC for 3–4 h. Mean data in A and B for untreated myocytes from diabetic and control rats are the same as in Table 1 and are shown for purposes of comparison.

 
Parallel confocal experiments were conducted to assess the effects of GSH and NAC on Ca2+ transients. Figure 6A shows that GSH and NAC treatment of diabetic rat myocytes increased the rate of Ca2+ rise and peak Ca2+, whereas it decreased the Ca2+ decay time. Similar to insulin experiments, neither GSH nor NAC significantly affected the kinetics of Ca2+ transients in control myocytes (Fig. 6B). However, in contrast to the effects on mechanical properties (Fig. 5), GSH and NAC both normalized parameters of the Ca2+ transients. Specifically, in diabetic rat myocytes treated with GSH, the rates of Ca2+ rise [103.1 ± 8.4 fluorescence intensity in arbitrary units (fau)/s], peak Ca2+ (2.06 ± 0.19 fau), and Ca2+ decay time (368.3 ± 20.0 ms) were not significantly different from GSH-treated control myocytes (119.1 ± 8.5 fau/s, 1.95 ± 0.10 fau, and 347.7 ± 29.6 ms, respectively). Similar findings were observed in diabetic and control myocytes treated with NAC (data not shown).


Figure 6
View larger version (46K):
[in this window]
[in a new window]

  		Fig. 6. Effect of exogenous GSH and NAC on Ca2+ transients. A: diabetic rat myocytes were preincubated for 3–4 h with 10 mmol/l GSH or NAC. Rate of Ca2+ rise, peak Ca2+, and decay of the transient (T50) were measured at 0.5 Hz. *P < 0.05 compared with untreated myocytes. B: Ca2+ transient parameters in control myocytes pretreated with GSH or NAC for 3–4 h. Mean data in A and B for untreated myocytes from diabetic and control rats are the same as in Table 1 and are shown for purposes of comparison.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
Oxidative stress and GSH in diabetic heart. Intracellular GSH is an essential tripeptide that directly or indirectly regulates a number of biological processes, such as antioxidant defenses, DNA synthesis, ion transport, enzyme activity, transcription, and signal transduction (9, 37, 38). Much of the control of these processes by GSH is mediated by its regulation of the redox state of protein thiol groups of cysteine residues, which determine the structure and activity of many proteins required for normal cell activity (36). Under oxidative stress conditions, free thiols can undergo a number of different modifications to yield unique chemical intermediates that can lead to a gain or loss of protein function. GSH has been shown to control the biological activity of proteins by preventing modification of thiols through detoxification of reactive oxygen species or by directly participating in the reduction of thiol intermediates (36). Consequently, maintenance of an adequate [GSH] is important for protecting protein thiol groups from oxidative modification. This is accomplished in mammalian cells through the activities of glutathione reductase, which converts GSSG to GSH using NADPH as a source of reducing equivalents, and {gamma}-glutamylcysteine synthetase, the rate-limiting step in de novo GSH synthesis (9, 20, 36–38).

Human and animal studies show that cardiovascular complications associated with diabetes are linked to oxidative stress (8, 12), which causes profound and dynamic changes in GSH status. For example, some studies have reported an increase in cardiac GSH content, suggesting that compensatory upregulation of GSH-related pathways occurs in response to oxidative conditions (46, 51). In agreement with this hypothesis, the activity of glutathione reductase has been shown to be increased in some studies (46, 51). However, GSH depletion is observed in most diabetic models, which is most likely a function of the duration of diabetic conditions or the severity of hyperglycemia (11, 50). This change in redox status reflects not only an increased GSH demand for antioxidant and conjugation reactions but also a decreased supply of GSH. In particular, our present study and others (11, 31) show that the activities of {gamma}-glutamylcysteine synthetase and glutathione reductase are decreased in the diabetic heart compared with control (Fig. 1, B and C). The loss of function of these key enzymes results in decreased rates of GSH synthesis and decreased regeneration of GSH from GSSG.

Glucose metabolism and GSH. Although glutathione reductase and {gamma}-glutamylcysteine synthetase are generally considered major enzymes involved in GSH homeostasis, upstream accessory pathways such as G6PD and pyruvate dehydrogenase have also been shown to be key factors affecting [GSH]. G6PD is the rate-limiting enzyme of the cytosolic pentose pathway that generates NADPH utilized by glutathione reductase (9, 36–38). Recent data show that targeted deficiency of G6PD in mice leads to GSH depletion, accumulation of GSSG, and impaired Ca2+ handling in ventricular myocytes (24). In experimental models of diabetes, variable changes in the activity of this enzyme have been reported (23, 51), and in our study we found no change in basal G6PD activity in diabetic hearts compared with control (Fig. 3C). Nevertheless, this enzyme played a key role in insulin-mediated normalization of [GSH], as evidenced by inhibitory effects of DHEA and 6-AN (Fig. 3A). Residual {gamma}-glutamylcysteine synthetase activity also contributed to GSH upregulation by insulin in diabetic rat myocytes, such that, when this enzyme was inhibited along with G6PD, insulin had no effect (Fig. 3B). Together, these findings indicate that an essential function of glucose metabolism in the heart, independent of ATP production, is the regulation of GSH levels for redox control of cell function.

In contrast to variable changes in G6PD, there is general agreement that the activity of pyruvate dehydrogenase is decreased in diabetic rat heart due to an increased state of phosphorylation mediated by pyruvate dehydrogenase kinase (19). DCA inhibits pyruvate dehydrogenase kinase, thereby stimulating overall pyruvate dehydrogenase activity and promoting glucose and pyruvate oxidation (1, 42). Moreover, DCA increases the supply of substrate for active pyruvate dehydrogenase by a concomitant increase in glucose and pyruvate uptake (30). In the present study, we found that DCA rapidly increased [GSH] to control levels in diabetic rat myocytes but that this effect was transient (Fig. 2A). Although we did not examine the mechanism for the decline in [GSH] with prolonged DCA exposure, which was also observed in control myocytes, previous studies suggest that this response may be due to glutathione-S-transferase-catalyzed conjugation of intracellular DCA with GSH (21), which would be expected to cause GSH depletion.

Despite evidence of its influence on GSH, the link between pyruvate dehydrogenase and GSH homeostasis is not fully understood. Experiments in isolated rat hearts suggest that increased pyruvate dehydrogenase activity leads to citrate accumulation that increases NADPH production by cytosolic isocitrate dehydrogenase or inhibits phosphofructokinase, thereby diverting glycolytic flux to NADPH-generating G6PD (42). Compared with DCA, insulin in our experiments produced a delayed but more sustained increase in [GSH] over a 6-h incubation period (Fig. 2A). The reason for the lag in response to insulin may simply be due to a dose effect; i.e., a higher insulin concentration would elicit a more rapid response. However, Lloyd et al. (30) reported that insulin and DCA exert quantitatively different effects on substrate oxidation in isolated rat heart. In particular, they showed that DCA exerts a more robust stimulation of pyruvate oxidation than insulin. This may be due to different mechanisms controlling the phosphorylation state of pyruvate dehydrogenase; i.e., DCA inhibits pyruvate dehydrogenase kinase (1, 42), whereas insulin increases pyruvate dehydrogenase phosphatase activity (29, 30). Alternatively, the different time course of GSH upregulation may be related to the more diverse metabolic effects of insulin on the myocardium compared with DCA, such as increased expression or activity of hexokinase (33) or {gamma}-glutamylcysteine synthetase (20) (Fig. 3D). There is no present compelling evidence that glutathione reductase is directly regulated by insulin (44), despite this enzyme being essential for GSH homeostasis. Indeed, our study found no significant change in glutathione reductase activity in the presence of insulin (Fig. 3D).

Cellular functions of GSH. GSH is a key molecule that regulates a multitude of physiological processes (9, 37, 38) through thiol-disulfide exchange reactions that directly involve GSH or that are catalyzed by the oxidoreductase glutaredoxin, which requires GSH as cofactor (15). Recent data suggest that GSH and glutaredoxin are important regulators of pathophysiological signals activated by oxidative stress, such as apoptosis (7, 22). We also found evidence of regulation of myocyte Ca2+ handling and mechanical properties by GSH in the present experiments (Figs. 5 and 6). Our findings are consistent with studies of G6PD deficiency in nondiabetic myocytes (24), which show similar degrees of GSH depletion and mechanical dysfunction as in our diabetic model. However, it is not known whether regulation of myocyte Ca2+ handling is mediated by the antioxidant or reducing properties of GSH. In the former case, GSH may protect Ca2+ handling proteins from oxidation by directly scavenging reactive oxygen species or by acting as cofactor for inactivation of hydroperoxides by glutathione peroxidase (10, 48). Alternatively, GSH may directly reduce oxidized protein thiols or participate as a cofactor for glutaredoxin-catalyzed thiol reduction (15). The same possible mechanisms also apply to NAC, which increases [GSH] in depleted myocytes (28) and which showed effects similar to GSH in the present study (Figs. 5 and 6). Additional investigation is necessary to better define the antioxidant and reducing effects of exogenous reductants.

It is clear that diabetes elicits significant contractile dysfunction in cardiomyocytes that is accompanied by Ca2+ dysregulation. Experimental studies of long-term diabetes (e.g., >8 wk; Ref. 6) generally show decreased expression of ryanodine receptors (RyR2), sarcoplasmic reticulum Ca2+-ATPase (SERCA2a), and the Na+/Ca2+ exchanger, which are postulated to contribute to an abnormal contractile phenotype (2, 6). Although some studies have shown a decrease in L-type Ca2+ current (3), most diabetic models report little change (6, 39). At earlier stages of the disease, as represented by the present study, RyR2 expression and SERCA2a expression are not significantly altered from control (2, 52), although Na+/Ca2+ exchanger expression may still be decreased (17). However, the relatively rapid (3–4 h) normalization of Ca2+ transients and mechanical properties by insulin (Table 1), GSH, and NAC (Figs. 5 and 6) in our study is more consistent with posttranslational changes in Ca2+ handling proteins than with changes in expression, and the effects of exogenous GSH and NAC further imply a redox mechanism. Indeed, experimental evidence shows that several Ca2+ handling proteins in myocytes are acutely modulated by redox-specific mechanisms. For example, exogenous thiol-reactive compounds inhibit L-type Ca2+ channels (5, 13) and enhance Ca2+-induced Ca2+ release from RyR2 (18) in a manner that is reversed by reducing agents such as dithiothreitol. These studies suggest that a pathophysiological shift in myocyte redox state, such as occurs in diabetes, promotes oxidative damage of specific Ca2+ handling proteins that contribute to contractile dysfunction. However, the precise modulation of protein damage by GSH or other endogenous reductants in the setting of diabetes is not well understood. Our study thus provides important functional insights into the repair capabilities of endogenous redox networks such as those utilizing GSH.

In summary, our data suggest that diabetes-induced loss of function of GSH regulatory enzymes contributes to depletion of GSH in ventricular myocytes. We postulate that insulin signaling regulates myocardial GSH through a coordinated activation of pathways involved in GSH synthesis and NADPH production. The status of GSH in turn impacts cardiomyocyte Ca2+ handling proteins and mechanical properties. Thus, it may be postulated that diabetes-mediated GSH depletion contributes to functional alterations in redox-sensitive Ca2+ handling proteins and that signaling pathways related to insulin are protective by virtue of their control of GSH availability for antioxidant and reducing functions.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by National Heart, Lung, and Blood Institute Grant HL-66446 (to G. J. Rozanski) and an American Diabetes Association grant (to G. J. Rozanski and K. R. Bidasee).


   FOOTNOTES
 

Address for reprint requests and other correspondence: G. J. Rozanski, Dept. of Cellular and Integrative Physiology, Univ. of Nebraska College of Medicine, 985850 Nebraska Medical Center, Omaha, NE 68198-5850 (e-mail: grozansk{at}unmc.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Bersin RM, Stacpoole PW. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J 134: 841–855, 1997.[CrossRef][ISI][Medline]
  2. Bidasee KR, Nallani K, Besch HR, Dincer UD. Streptozotocin-induced diabetes increases disulfide bond formation on cardiac ryanodine receptor (RyR2). J Pharmacol Exp Ther 5: 989–998, 2003.
  3. Bracken NK, Woodall AJ, Howarth FC, Singh J. Voltage-dependence of contraction in streptozotocin-induced diabetic myocytes. Mol Cell Biochem 261: 235–243, 2004.[CrossRef][ISI][Medline]
  4. Carlberg I, Mannervik B. Glutathione reductase. Methods Enzymol 113: 484–490, 1985.[ISI][Medline]
  5. Chiamvimonvat N, O'Rourke B, Kamp TJ, Kallen RG, Hofmann F, Flockerzi V, Marban E. Functional consequences of sulfhydryl modification in the pore-forming subunits of cardiovascular Ca2+ and Na+ channels. Circ Res 76: 325–334, 1995.[Abstract/Free Full Text]
  6. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, Lederer WJ, Matlib MA. Defective intracellular Ca2+ signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol 283: H1398–H1408, 2002.[Abstract/Free Full Text]
  7. Curtin JF, Donovan M, Cotter TG. Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods 265: 49–72, 2002.[CrossRef][ISI][Medline]
  8. De Cavanagh EM, Inserra F, Toblli J, Stella I, Fraga CG, Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension 38: 1130–1136, 2001.[Abstract/Free Full Text]
  9. Deneke SM. Thiol-based antioxidants. Curr Top Cell Regul 36: 151–180, 2000.[ISI][Medline]
  10. Dickinson DA, Forman HJ. Glutathione in defense and signaling. Lessons from a small thiol. Ann NY Acad Sci 973: 488–504, 2002.[ISI][Medline]
  11. Doi K, Sawada F, Toda G, Yamachika S, Seto S, Urata Y, Ihara Y, Sakata N, Taniguchi N, Kondo T, Yano K. Alteration of antioxidants during the progression of heart disease in streptozotocin-induced diabetic rats. Free Radic Res 34: 251–261, 2001.[ISI][Medline]
  12. Esposito K, Marfella R, Giugliano D. Hyperglycemia and heart dysfunction: an oxidant mechanism contributing to heart failure in diabetes. J Endocrinol Invest 25: 485–488, 2002.[ISI][Medline]
  13. Fearon IM, Palmer ACV, Balmforth AJ, Ball SG, Varadi G, Peers C. Modulation of recombinant human cardiac L-type Ca2+ channel {alpha}1C subunits by redox agents and hypoxia. J Physiol 514: 629–637, 1999.[Abstract/Free Full Text]
  14. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 8: 65–73, 1994.[CrossRef][ISI][Medline]
  15. Fernandes AP, Holmgren A. Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antiox Redox Signal 6: 63–74, 2004.[CrossRef][ISI][Medline]
  16. Goldhaber JI, Qayyum MS. Oxygen free radicals and excitation-contraction coupling. Antiox Redox Signal 2: 55–64, 2000.[Medline]
  17. Hattori Y, Matsuda N, Kimura J, Ishitani T, Tamada A, Gando S, Kemmotsu O, Kanno M. Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload. J Physiol 527: 85–94, 2000.[Abstract/Free Full Text]
  18. Hidalgo C, Bull R, Beherens MI, Donoso P. Redox regulation of RyR-mediated Ca2+ release in muscle and neurons. Biol Res 37: 539–552, 2004.[ISI][Medline]
  19. Huang B, Wu P, Popov KM, Harris RA. Starvation and diabetes reduce the amount of pyruvate dehydrogenase phosphatase in rat heart and kidney. Diabetes 52: 1371–1376, 2003.[Abstract/Free Full Text]
  20. Huang ZZ, Yang H, Chen C, Zeng Z, Lu SC. Inducers of {gamma}-glutamylcysteine synthetase and their effects on glutathione synthetase expression. Biochim Biophys Acta 1493: 48–55, 2000.[Medline]
  21. Huey-Fen T, Blackburn AC, Board PG, Anders MW. Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. Chem Res Toxicol 13: 231–236, 2000.[CrossRef][ISI][Medline]
  22. Inserte J, Taimor G, Hofstaetter B, Garcia-Dorado D, Piper HM. Influence of simulated ischemia on apoptosis induction by oxidative stress in adult cardiomyocytes of rats. Am J Physiol Heart Circ Physiol 278: H94–H99, 2000.[Abstract/Free Full Text]
  23. Irlbeck M, Zimmer HG. The functional and metabolic responses of the heart to catecholamines are attenuated in diabetic rats. Cardioscience 6: 131–138, 1995.[ISI][Medline]
  24. Jain M, Brenner DA, Cui L, Lim CC, Wang B, Pimentel DR, Koh S, Sawyer DB, Leopold JA, Handy DE, Loscalzo J, Apstein CS, Liao R. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res 93: e9–e16, 2003.[Abstract/Free Full Text]
  25. Johnson SA, Denton RM. Insulin stimulation of pyruvate dehydrogenase in adipocytes involves two distinct signaling pathways. Biochem J 369: 351–356, 2003.[CrossRef][ISI][Medline]
  26. Le CT, Hollaar L, Van der Valk EJM, Van der Laarse A. Buthionine sulfoxamine reduces the protective capacity of myocytes to withstand peroxide-derived free radical attack. J Mol Cell Cardiol 25: 519–528, 1993.[CrossRef][ISI][Medline]
  27. Li S, Li X, Rozanski GJ. Regulation of glutathione in cardiac myocytes. J Mol Cell Cardiol 35: 1145–1152, 2003.[CrossRef][ISI][Medline]
  28. Li X, Li S, Xu Z, Lou MF, Anding P, Liu D, Roy SK, Rozanski GJ. Redox control of K+ channel remodeling in rat ventricle. J Mol Cell Cardiol 40: 339–349, 2006.[CrossRef][ISI][Medline]
  29. Lilley K, Zhang C, Villar-Palasi C, Larner J, Huang L. Insulin mediates stimulation of pyruvate dehydrogenase phosphatases. Arch Biochem Biophys 296: 170–174, 1992.[CrossRef][ISI][Medline]
  30. Lloyd S, Brocks C, Chatham JC. Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart. Am J Physiol Heart Circ Physiol 285: H163–H172, 2003.[Abstract/Free Full Text]
  31. Mak DHF, Ip SP, Li PC, Poon MKT, Ko KM. Alterations in tissue glutathione antioxidant system in streptozotocin-induced diabetic rats. Mol Cell Biochem 162: 153–158, 1996.[ISI][Medline]
  32. Mahgoub MA, Abd-Elfattah AS. Diabetes mellitus and cardiac function. Mol Cell Biochem 180: 59–64, 1998.[CrossRef][ISI][Medline]
  33. Osawa H, Sutherlan C, Robey RB, Prinz RL, Granner DK. Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin. J Biol Chem 271: 16690–166694, 1996.[Abstract/Free Full Text]
  34. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27: 169–179, 1995.[ISI][Medline]
  35. Rozanski GJ, Xu Z. Glutathione and K+ channel remodeling in postinfarction rat heart. Am J Physiol Heart Circ Physiol 282: H2346–H2355, 2002.[Abstract/Free Full Text]
  36. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30: 1191–1212, 2001.[CrossRef][ISI][Medline]
  37. Seelig GF, Meister A. Glutathione synthesis: {gamma}-glutamylcysteine synthetase from rat kidney. Methods Enzymol 113: 379–390, 1985.[ISI][Medline]
  38. Sen CK. Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 36: 1–30, 2000.[ISI][Medline]
  39. Shao CH, Rozanski GJ, Patel KP, Bidasee KR. Dyssynchronous (non-uniform) Ca2+ release in myocytes from streptozotocin-induced diabetic rats. J Mol Cell Cardiol 42: 234–246, 2007.[CrossRef][ISI][Medline]
  40. Shehadeh A, Regan TJ. Cardiac consequences of diabetes mellitus. Clin Cardiol 18: 301–305, 1995.[ISI][Medline]
  41. Sochor M, Gonzalez AM, McLean P. Regulation of alternative pathways of glucose metabolism in rat heart in alloxan diabetes: changes in the pentose phosphate pathway. Biochem Biophys Res Commun 118: 110–116, 1984.[CrossRef][ISI][Medline]
  42. Squires JE, Sun J, Caffrey JL, Yoshishige D, Mallet RT. Acetoacetate augments beta-adrenergic inotropism of stunned myocardium by an antioxidant mechanism. Am J Physiol Heart Circ Physiol 284: H1340–H1347, 2003.[Abstract/Free Full Text]
  43. Strother RM, Thomas TG, Otsyula M, Sanders RA, Watkins JB. Characterization of oxidative stress in various tissues of diabetic and galactose-fed rats. Int J Exp Diabetes Res 2: 211–216, 2001.[Medline]
  44. Tagami S, Kondo T, Yoshida K, Hirokawa J, Ohtsuka Y, Kawakami Y. Effect of insulin on impaired antioxidant activities in aortic endothelial cells from diabetic rabbits. Metabolism 41: 1053–1058, 1992.[CrossRef][ISI][Medline]
  45. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27: 502–522, 1969.[CrossRef][ISI][Medline]
  46. Toleikis PM, Godin DV. Alteration of antioxidant status in diabetic rats by chronic exposure to psychological stressors. Pharmacol Biochem Behav 52: 355–366, 1995.[CrossRef][ISI][Medline]
  47. Wagle A, Jivraj S, Garlock GL, Stapleton SR. Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is rapamycin-sensitive and requires phosphatidylinositol 3-kinase. J Biol Chem 273: 14968–14974, 1998.[Abstract/Free Full Text]
  48. Winterbourn CC. Superoxide as an intracellular radical sink. Free Radic Biol Med 14: 85–90, 1993.[CrossRef][ISI][Medline]
  49. Xu Z, Patel KP, Rozanski GJ. Metabolic basis of decreased transient outward K+ current in ventricular myocytes from diabetic rats. Am J Physiol Heart Circ Physiol 271: H190–H2196, 1996.
  50. Xu Z, Patel KP, Lou MF, Rozanski GJ. Up-regulation of K+ channels in diabetic rat ventricular myocytes by insulin and glutathione. Cardiovasc Res 53: 80–88, 2002.[Abstract/Free Full Text]
  51. Yadav P, Sarkar S, Bhatnagar D. Action of Capparis decidua against alloxan-induced oxidative stress and diabetes in rat tissues. Pharmacol Res 36: 221–228, 1997.[CrossRef][ISI][Medline]
  52. Zhong Y, Ahmed A, Grupp IL, Matlib MA. Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am J Physiol Heart Circ Physiol 281: H1137–H1147, 2001.[Abstract/Free Full Text]
  53. Zuurbier CJ, Eerbeek O, Goedhart PT, Struys EA, Verhoeven NM, Jakobs C, Ince C. Inhibition of the pentose pathway decreases ischemia-reperfusion-induced creatine kinase release in the heart. Cardiovasc Res 62: 145–153, 2004.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 QJMHome page
W.S. Waring, A.F.L. Stephen, O.D.G. Robinson, M.A. Dow, and J.M. Pettie
Serum urea concentration and the risk of hepatotoxicity after paracetamol overdose
QJM, May 1, 2008; 101(5): 359 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. Li, X. Li, H. Zheng, B. Xie, K. R. Bidasee, and G. J. Rozanski
Pro-oxidant effect of transforming growth factor-{beta}1 mediates contractile dysfunction in rat ventricular myocytes
Cardiovasc Res, January 1, 2008; 77(1): 107 - 117.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/3/H1619    most recent
00140.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow